This week's View offers key points to remember from a review about the use of cardiovascular medications during pregnancy, key points to remember from the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, and highlights from a subsequent analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, AHA18, AHA Annual Scientific Sessions, ACC18, ACC Annual Scientific Session, Acute Coronary Syndrome, Adrenergic beta-Agonists, Angiotensin-Converting Enzyme Inhibitors, Angina, Unstable, Anti-Arrhythmia Agents, Antibodies, Monoclonal, Humanized, Apolipoproteins B, Arrhythmias, Cardiac, Anticoagulants, Atrial Fibrillation, Brain Ischemia, Aspirin, Catheter Ablation, Atrial Appendage, Cholesterol, HDL, Cholesterol, LDL, Diabetes Mellitus, Cost-Benefit Analysis, Coronary Disease, Dyslipidemias, Heart Failure, Gestational Age, Heart Valve Diseases, Heparin, Heparin, Low-Molecular-Weight, Hemorrhage, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypotension, Hypertension, Lipids, Monitoring, Ambulatory, Mitral Valve Stenosis, Myocardial Infarction, Myocardial Revascularization, Overweight, Obesity, Pharmacokinetics, Pre-Eclampsia, Prostaglandins, Platelet Aggregation Inhibitors, Risk Factors, Secondary Prevention, Stents, Pregnancy, Primary Prevention, Stroke, Stroke Volume, Renal Dialysis, Treatment Outcome, Warfarin, Women, Weight Loss, Wolff-Parkinson-White Syndrome

< Back to Listings